SAN FRANCISCO, Aug. 2, 2016 /PRNewswire-iReach/ -- Pancreum, Inc. ("Pancreum" www.pancreum.com) announced today that it was awarded U.S. Patent No. US9248235, which protects its innovative Disease Management System consisting of a reusable programmable core (CoreMD) that controls various disposable sensors and drug delivery devices. This patent further protects the ability for the CoreMD to wirelessly communicate and power the various sensors and drug delivery devices. Pancreum further announced that it was previously awarded U.S. Design Patent No. USD704325, which protects its uniquely designed system, also referred to as Genesis.
Photo - http://photos.prnewswire.com/prnh/20160729/394321
In addition, Pancreum has recently added to its research and development team by bringing on Steve DiIanni who was the former Director of Mechanical Engineering at Insulet Corporation. Steve has over 25 years of experience in the medical industry designing insulin pumps and will now be leading Pancreum in finalizing a clinical-ready insulin delivery system.
Jerry Joseph, Pancreum's co-founder and legal counsel, will now take on the position as Chief Executive Officer (CEO) as Guilherme de Paula, Pancreum's Founder and current CEO, concentrates on leading Pancreum's product development efforts as Chief Technology Officer (CTO). This re-organization allows Gil DePaula to concentrate his efforts on the development of the clinical ready pump and system.
Jerry has expressed that "these issued patents together with the addition of key industry leaders strengthen Pancreum's position within the diabetes industry, as well as in large molecule and large volume drug delivery markets." Pancreum will continue to work with a unified vision in helping those with diabetes and various other chronic conditions. Jerry will focus on establishing further strategic partners, as well as securing additional funding to bring our products to market.
About Pancreum
Pancreum is a development-stage medical device company that is developing an affordable multi-drug delivery platform, which may be used to address numerous chronic health conditions, such as diabetes.
Pancreum is developing a low-cost semi-disposable diabetes management system (Genesis), which has the ability to function as a bionic pancreas. The Genesis system includes a reusable wearable core (CoreMD) onto which various disposable drug delivery modules and sensor modules may be attached. The system may function as an artificial pancreas when an insulin delivery module, a continuous glucose sensing module, and a glucagon delivery module are attached to the CoreMD. The system may then work together in unison to help manage and treat diabetes.
Follow our development news at our accounts on Twitter, Facebook, LinkedIn, YouTube, and Google+.
Media Contact:Jerry Joseph, Pancreum, Inc., (202) 570-4009, moreinfo@pancreum.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Pancreum, Inc.
